-
-
NCT01591122
-
Primary Citation
Not Yet Available
-
Data Specification
Not Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameAbiraterone acetateProduct NameZYTIGA®Therapeutic AreaCancers and Other NeoplasmsEnrollment313% FemaleN/A% WhiteN/A
Product ClassHormonesSponsor Protocol NumberABI-PRO-3002Data PartnerJohnson & JohnsonCondition StudiedNeoplasms, ProstaticMean/Median Age (Years)71
Supporting Documentation
- Collected Datasets Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2023-5236 : Understanding the Symptom Experience of Abiraterone and the Effect on Quality of Life for Men with metastatic Prostate Cancer.
- 2023-5215 : Analysis of adverse events of prostate cancer drugs targeting on the hypothalamic pituitary gonadal axis
- 2023-5198 : Evaluation of G-computation and conformal prediction to provide early signs of efficacy in single arm trial with time to event outcomes
- 2022-5125 : Risk of therapy-related adverse events in men on abiraterone or enzalutamide, a meta-analysis of clinical trial data
- 2022-5106 : Assessing the Androgen indifferent prostate cancer patients response to novel antiandrogen-based regimen or taxanes
- 2022-5030 : Overall Survival and Radiographic Progression Free Survival difference among Asian, White and Black mCRPC patients treated with Abiraterone
- 2022-4974 : Association between adverse events and change in quality-of-life scores in phase II-III cancer clinical trials
- 2021-4841 : The Impact of Second Generation Anti-Androgens on Quality of Life in Men with Advanced Prostate Cancer
- 2021-4740 : The Impact of Second Generation Anti-Androgens on Sexual Function in Men with Advanced Prostate Cancer